Oncogenic Kras drives invasion and maintains metastases in colorectal cancer

Human colorectal cancer (CRC) is a major cause of cancer mortality and frequently harbors activating mutations in the KRAS gene. To understand the role of oncogenic KRAS in CRC, we engineered a mouse model of metastatic CRC that harbors an inducible oncogenic Kras allele (Krasmut ) and conditional null alleles of Apc and Trp53 (iKAP). The iKAP model recapitulates tumor progression from adenoma through metastases. Whole-exome sequencing revealed that the Krasmut allele was heterogenous in primary tumors yet homogenous in metastases, a pattern consistent with activated Krasmut signaling being a driver of progression to metastasis. System-level and functional analyses revealed the TGF-β pathway as a key mediator of Krasmut -driven invasiveness. Genetic extinction of Krasmut resulted in specific elimination of the Krasmut subpopulation in primary and metastatic tumors, leading to apoptotic elimination of advanced invasive and metastatic disease. This faithful CRC model provides genetic evidence that Krasmut drives CRC invasion and maintenance of metastases.

[1]  C. Iacobuzio-Donahue,et al.  TGF-β Tumor Suppression through a Lethal EMT , 2016, Cell.

[2]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[3]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[4]  Hans Clevers,et al.  Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer , 2015, Cell.

[5]  J. Vauthey,et al.  Association between KRAS mutation and lung metastasis in advanced colorectal cancer , 2014, British Journal of Cancer.

[6]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[7]  Inna Kuperstein,et al.  Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut , 2014, Nature Communications.

[8]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[9]  Doulaye Dembélé,et al.  Fold change rank ordering statistics: a new method for detecting differentially expressed genes , 2014, BMC Bioinformatics.

[10]  J. Fleet,et al.  Animal models of colorectal cancer , 2012, Cancer and Metastasis Reviews.

[11]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[12]  Abdul Mannan,et al.  K‐ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[14]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[15]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[16]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[17]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[18]  V. Heinemann,et al.  Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status , 2011, Anti-cancer drugs.

[19]  Xin Wang,et al.  KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. , 2011, Oncology reports.

[20]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[21]  P. Snyder,et al.  Generation of a Transgenic Mouse for Colorectal Cancer Research with Intestinal Cre Expression Limited to the Large Intestine , 2010, Molecular Cancer Research.

[22]  P. Devilee,et al.  A new conditional Apc-mutant mouse model for colorectal cancer. , 2010, Carcinogenesis.

[23]  Nicholas D. Socci,et al.  Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal , 2010, Nature.

[24]  Umar Mahmood,et al.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment , 2010, Proceedings of the National Academy of Sciences.

[25]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[26]  B. Spencer‐Dene,et al.  The Apc 1322T mouse develops severe polyposis associated with submaximal nuclear beta-catenin expression. , 2009, Gastroenterology.

[27]  Sharmistha Sarkar,et al.  A Two-Step Model for Colon Adenoma Initiation and Progression Caused by APC Loss , 2009, Cell.

[28]  M. Taketo,et al.  Mouse models of colon cancer. , 2009, Gastroenterology.

[29]  Barbara L Parsons,et al.  Many different tumor types have polyclonal tumor origin: evidence and implications. , 2008, Mutation research.

[30]  N. Wright,et al.  Colonic crypt organization and tumorigenesis , 2008, Nature Reviews Cancer.

[31]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[32]  Kathleen R. Cho,et al.  Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. , 2007, Cancer research.

[33]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[34]  Miguel Abal,et al.  APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. , 2006, Gastroenterology.

[35]  Julie A. Wilkins,et al.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo , 2006, Proceedings of the National Academy of Sciences.

[36]  Jennifer J. Lund,et al.  Adenomatous Polyposis Coli (APC) Is Required for Normal Development of Skin and Thymus , 2006, PLoS genetics.

[37]  Stephen A. Stanhope,et al.  Polyclonality of familial murine adenomas: analyses of mouse chimeras with low tumor multiplicity suggest short-range interactions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Whitsett,et al.  Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction , 2005, Nucleic acids research.

[39]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[40]  Daniel Metzger,et al.  Tissue‐specific and inducible Cre‐mediated recombination in the gut epithelium , 2004, Genesis.

[41]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[42]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[43]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[44]  W. Bodmer,et al.  Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. , 2003, Cancer research.

[45]  A. Berns,et al.  Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.

[46]  H. Sheng,et al.  Transforming Growth Factor-β1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells , 2001 .

[47]  J. Gordon,et al.  Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Wakitani,et al.  Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. , 2000, Carcinogenesis.

[49]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[50]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[51]  T. Noda,et al.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. , 1997, Science.

[52]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[53]  W. Bodmer,et al.  Polyclonal Origin of Colonic Adenomas in an XO/XY Patient with FAP , 1996, Science.

[54]  M Oshima,et al.  Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R Fodde,et al.  A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Kinzler,et al.  Erratum: Multiple Intestinal Neoplasia Caused By a Mutation in the Murine Homolog of the APC Gene , 1992, Science.

[57]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[58]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[59]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.